Featured Studies Results

Vaccines for Pancreatic Cancer After Chemotherapy and Prior to Surgery

https://www.facingourrisk.org/research-clinical-trials/study/318/vaccines-for-pancreatic-cancer-after-chemotherapy-and-prior-to-surgery

Clinicaltrials.gov identifier:
NCT05111353 (https://clinicaltrials.gov/show/NCT05111353)

Treatment
Vaccine study for people diagnosed with pancreatic cancer

---

Effectiveness of Lymph Node Mapping to Reduce the Risk of Swelling in the Legs in Patients with Stage I Endometrial Cancer

https://www.facingourrisk.org/research-clinical-trials/study/310/effectiveness-of-lymph-node-mapping-to-reduce-the-risk-of-swelling-in-the-legs-in-patients-with-stage-i-endometrial-cancer

Clinicaltrials.gov identifier:
NCT05646316 (https://clinicaltrials.gov/show/NCT05646316)

Treatment
People with stage I endometrial cancer who are having a hysterectomy

---

The Phoenix Trial: Cemiplimab for Patients with Localized dMMR Colon Cancer

https://www.facingourrisk.org/research-clinical-trials/study/299/the-phoenix-trial-cemiplimab-for-patients-with-localized-dmmr-colon-cancer

Clinicaltrials.gov identifier:
NCT05961709 (https://clinicaltrials.gov/show/NCT05961709)

Treatment
This study will examine how well Cemiplimab works for patients with localized colon cancer who have dMMR

---

Studying a Combination of Three Drugs to Treat Previously Untreated Metastatic Colorectal Cancer which Is MSI-High and Has a BRAF V600E Mutation

https://www.facingourrisk.org/research-clinical-trials/study/252/comparing-three-drugs-in-patients-with-metastatic-colorectal-cancer-who-have-not-had-prior-treatment

Clinicaltrials.gov identifier:
NCT05217446 (https://clinicaltrials.gov/show/NCT05217446)

Treatment
Study for metastatic colorectal cancer that has not yet been treated

---

Using ctDNA Blood Test for Earlier Detection and Treatment of Recurrence or Spread after Treatment for Stage 3 Colon Cancer

https://www.facingourrisk.org/research-clinical-trials/study/283/using-ctdna-for-earlier-detection-and-treatment-of-recurrence-or-spread-after-treatment-for-stage-3-colon-cancer

Clinicaltrials.gov identifier:
NCT03803553 (https://clinicaltrials.gov/show/NCT03803553)

Treatment
Monitoring and treatment study for people who completed treatment for stage 3 colon cancer

---

Comparing a Combination of Drugs for Treatment of HER2-positive Colorectal Cancer as First Line Treatment in the Metastatic Setting

https://www.facingourrisk.org/research-clinical-trials/study/274/treatment-of-her2-positive-colorectal-cancer-as-first-line-treatment-in-the-metastatic-setting

Clinicaltrials.gov identifier:
NCT05253651 (https://clinicaltrials.gov/show/NCT05253651)

Treatment
People with HER2-positive colorectal cancer who have not yet received treatment in the metastatic setting

---

Study of Colorectal Cancer and Genetics in Hispanic and Latino People (ENLACE Study)

https://www.facingourrisk.org/research-clinical-trials/study/276/study-of-colorectal-cancer-and-genetics-in-hispanic-and-latino-people-enlace-study

Treatment
Hispanic and Latino people diagnosed with colorectal cancer

---

Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient (dMMR/MSI-High) Cancers Resistant to Prior PD-L1 Inhibitor

https://www.facingourrisk.org/research-clinical-trials/study/151/nivolumab-and-relatlimab-in-advanced-msi-h-cancers-resistant-to-prior-pd-l1-inhibitor

Clinicaltrials.gov identifier:
NCT03607890 (https://clinicaltrials.gov/show/NCT03607890)

Treatment
Solid tumors that are MSI-High and resistant to prior immunotherapy

---

Chemotherapy, Bevacizumab, and/or Atezolizumab for Patients With Deficient DNA Mismatch Repair (dMMR or MSI-H) Metastatic Colorectal Cancer, the COMMIT Study

https://www.facingourrisk.org/research-clinical-trials/study/126/chemotherapy-bevacizumab-andor-atezolizumab-for-dmmr-msi-h-metastatic-colorectal-cancer-commit-study

Clinicaltrials.gov identifier:
NCT02997228 (https://clinicaltrials.gov/show/NCT02997228)

Treatment
This is a treatment study is for people with metastatic colorectal cancer

---

A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) (CheckMate 8HW)

https://www.facingourrisk.org/research-clinical-trials/study/112/nivolumab-nivolumab-plus-ipilimumab-or-chemotherapy-for-microsatellite-instability-high-msi-h-metastatic-colorectal-cancer-checkmate-8hw

Clinicaltrials.gov identifier:
NCT04008030 (https://clinicaltrials.gov/show/NCT04008030)

Treatment
People with metastatic colorectal cancer that is MSI-High

---